Vesikari, T., Langley, J. M., Segall, N., Ward, B. J., Cooper, C., Poliquin, G., Smith, B., Gantt, S., McElhaney, J. E., Dionne, M., van Damme, P., Leroux-Roels, I., Leroux-Roels, G., Machluf, N., Spaans, J. N., Yassin-Rajkumar, B., Anderson, D. E., Popovic, V., Diaz-Mitoma, F., , , Vesikari, T., Langley, J. M., Gantt, S., Dionne, M., McElhaney, J., Rankin, B., Griffin, C., Turner, M., Kirstein, J., Rizzardi, B. E., Williams, H., Ahonen, A., Henriksson, O., Ukkonen, B., Paassilta, M., Segall, N., Ward, B. J., Cooper, C., Poliquin, G., Smith, B., Van Damme, P., Leroux-Roels, I., Leroux-Roels, G., Machluf, N., Spaans, J. N., Yassin-Rajkumar, B., Anderson, D. E., Popovic, V., & Diaz-Mitoma, F. (2021). immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet infectious diseases, 21(9), 1271–1281. http://access.bl.uk/ark:/81055/vdc_100144253245.0x000016